circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway

Published:2020-09 Issue: Volume:21 Page:885-899
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Huang Yutang,Dai Yi,Wen Chunjie,He Shuai,Shi Jingjing,Zhao Dezhang,Wu Lanxiang,Zhou Honghao

Funder

National Scientific Foundation of China

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference51 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. New molecular targeted therapies integrated with radiation therapy in lung cancer;Provencio;Clin. Lung Cancer,2010

3. Age is a prognostic factor affecting survival in lung cancer patients;Tas;Oncol. Lett.,2013

4. The EGF receptor system as a target for antitumor therapy;Ennis;Cancer Invest.,1991

5. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance;Jutten;Cell Cycle,2014

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circular RNAs in lung cancer: implications for preventing therapeutic resistance;eBioMedicine;2024-09

2. ABCG2 predicts the prognosis and is associated with immune infiltration in lung cancer: a bioinformatics study;2024-08-10

3. Examining the evidence for mutual modulation between m6A modification and circular RNAs: current knowledge and future prospects;Journal of Experimental & Clinical Cancer Research;2024-08-03

4. CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer;Cancer Genetics;2024-06

5. CircRNAs in cancer therapy tolerance;Clinica Chimica Acta;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3